Central Nervous System News and Research

RSS

Novel financing technique may unlock funding for developing 'orphan' drugs to treat rare diseases

A paper published today, "Financing translation: Analysis of the NCATS rare-diseases portfolio" in Science Translational Medicine, demonstrates the potential of a new financing technique to reduce the risk associated with investing in the treatment of new diseases and potentially unlock new levels of funding for developing so-called "orphan" drugs.

28 Feb 2015

Study suggests benefits of calorie restriction on healthy aging

Targeting mechanisms in the central nervous system that sense energy generated by nutrients might yield the beneficial effects of low-calorie diets on healthy aging without the need to alter food intake, suggests new research from Harvard T.H. Chan School of Public Health.

27 Feb 2015

AGA receives gift to support young investigators advance into neuroenteric disease research

The American Gastroenterological Association Research Foundation has received a generous gift from prominent San Francisco philanthropist Athena Blackburn, which will create new research opportunities for young investigators who are interested in neuroenteric disease.

26 Feb 2015

Prexton closes €8.7 million in Series A financing to develop treatments for Parkinson’s disease

Prexton Therapeutics, a biopharmaceutical company developing novel therapeutic compounds for the treatment of CNS conditions including Parkinson’s disease, today announces the closing of a Series A financing of €8.7 million ($10 million) co-led by Sunstone Capital and Ysios Capital.

26 Feb 2015

Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

A drug used to treat patients with Crohn's disease and multiple sclerosis has helped scientists confirm how "viral reservoirs" form in patients living with HIV and also proven effective in animal trials at blocking the pathways to those reservoirs in the brain and gut, a team of researchers reported recently in the journal PLOS Pathogens.

19 Feb 2015

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

18 Feb 2015

CAMH scientists discover potential new approach to treat multiple sclerosis

Scientists at the Centre for Addiction and Mental Health have discovered a promising new approach to treat multiple sclerosis (MS). In a new study, they've identified a previously unknown change in the spinal cord related to MS, and a way to alter this change to reduce the nerve cell damage that occurs with the disease.

18 Feb 2015

Stem cell transplants more effective than mitoxantrone drug for people with severe multiple sclerosis

Stem cell transplants may be more effective than the drug mitoxantrone for people with severe cases of multiple sclerosis (MS), according to a new study published in the February 11, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

12 Feb 2015

Peanut-shaped exercise ball promotes positive labor outcomes, reduces duration of delivery process

According to a new study by nurse researchers at Banner Good Samaritan Medical Center, a Phoenix hospital part of Banner Health, a peanut-shaped exercise ball can be a highly effective tool to accelerate the labor process for women with an epidural. The research shows women utilizing the peanut ball were half as likely to undergo a cesarean surgery and delivered babies faster than those who did not use the ball.

12 Feb 2015

ADDF, Pfizer's CTI collaborate to advance development of new drugs for Alzheimer's disease

The Alzheimer's Drug Discovery Foundation and Pfizer's Centers for Therapeutic Innovation announced today a collaboration designed to advance the development of new small-molecule drugs for Alzheimer's disease and related dementias. As part of the first-of-its kind collaboration in Alzheimer's, the ADDF and CTI will jointly invest in translational research projects, with a focus on novel Alzheimer's drug targets.

11 Feb 2015

UC San Diego School of Medicine project receives 2015 Avant-Garde Award for HIV/AIDS Research

A University of California, San Diego School of Medicine project involving the creation of miniature models of the human brain - developed with stem cells - to study neurological disorders caused by HIV and methamphetamine use has been named one of five recipients of the 2015 Avant-Garde Award for HIV/AIDS Research from the National Institute on Drug Abuse.

11 Feb 2015

UM one step closer to developing potential drug for treating brain cancer

Promentis Pharmaceuticals, Inc. recently announced it will enter an exclusive agreement with UM to commercialize a discovery made by a team of UM faculty scientists that has the potential to treat brain cancer and possibly other disorders of the central nervous system.

11 Feb 2015

TUSM researchers awarded $7.4 million to study brain impairment in patients infected with HIV

Researchers at Temple University School of Medicine have been awarded a $7.4 million, five-year grant from the National Institute on Drug Abuse to determine how cocaine and HIV-1 interact to cause brain impairment in patients infected with the human immunodeficiency virus.

11 Feb 2015

Epigem contribute to PhD research into Multiple Sclerosis

Epigem, a high-tech British micro engineering company, is supporting research into Multiple Sclerosis (MS) with a new PhD programme to create a novel drug screening platform. This will accelerate the production of MS models and pre-clinical drug development, in order to understand better the disease process and its periods of remission.

10 Feb 2015

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.

10 Feb 2015

Five researchers selected to receive 2015 Avant-Garde Award for HIV/AIDS Research

With proposals ranging from innovative therapies to the development of unique organoid models of the brain, five scientists have been selected to receive the 2015 Avant-Garde Award for HIV/AIDS Research from the National Institute on Drug Abuse, part of the National Institutes of Health. The five scientists will each receive $500,000 per year for five years to support their research.

10 Feb 2015

Researchers document pathological progress of multiple sclerosis

The Centre for Brain Research at the MedUni Vienna is regarded as a world leader in researching the mechanisms involved with multiple sclerosis (MS). Now, in a paper published in the highly respected journal Lancet Neurology, an international team of researchers from Edinburgh, Cleveland and Vienna, under the leadership of Hans Lassmann, Head of the Department of Neuroimmunology at the MedUni Vienna, has for the first time documented the pathological progress of the disease from its early to late stage and also shown that inflammatory and neurodegenerative processes have a role to play.

9 Feb 2015

Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration ("FDA") for REOLYSIN® for the treatment of high grade gliomas (HGG) in pediatric patients.

9 Feb 2015

UVA researchers find biological trigger for protective form of immune response to spinal cord injury

Hot on the heels of discovering a protective form of immune response to spinal cord injury, researchers at the University of Virginia School of Medicine have pinpointed the biological trigger for that response - a vital step toward being able to harness the body's defenses to improve treatment for spine injuries, brain trauma, Alzheimer's disease and other neurodegenerative conditions.

8 Feb 2015

Research findings could lead to improved treatments for brain and spinal cord injuries

6 Feb 2015

Central Nervous System News and Research

Novel financing technique may unlock funding for developing 'orphan' drugs to treat rare diseases

Study suggests benefits of calorie restriction on healthy aging

AGA receives gift to support young investigators advance into neuroenteric disease research

Prexton closes €8.7 million in Series A financing to develop treatments for Parkinson’s disease

Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

Actavis provides overview of standalone global pharmaceutical development pipeline

CAMH scientists discover potential new approach to treat multiple sclerosis

Stem cell transplants more effective than mitoxantrone drug for people with severe multiple sclerosis

Peanut-shaped exercise ball promotes positive labor outcomes, reduces duration of delivery process

ADDF, Pfizer's CTI collaborate to advance development of new drugs for Alzheimer's disease

UC San Diego School of Medicine project receives 2015 Avant-Garde Award for HIV/AIDS Research

UM one step closer to developing potential drug for treating brain cancer

TUSM researchers awarded $7.4 million to study brain impairment in patients infected with HIV

Epigem contribute to PhD research into Multiple Sclerosis

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Five researchers selected to receive 2015 Avant-Garde Award for HIV/AIDS Research

Researchers document pathological progress of multiple sclerosis

Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients

UVA researchers find biological trigger for protective form of immune response to spinal cord injury

Research findings could lead to improved treatments for brain and spinal cord injuries

Event guide: The 7th CNS Drug Delivery Summit eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News